Medikamentös-induzierte Polyneuropathien jenseits von Chemotherapeutika und Antiinfektiva

Zahlreiche in der klinischen Routine eingesetzte Wirkstoffe jenseits von Chemotherapeutika und Antiinfektiva können eine Polyneuropathie verstärken oder hervorrufen. Kenntnis darüber, welche Medikamente mit Polyneuropathien assoziiert sind sowie über Risikofaktoren seitens der Patienten können die Häufigkeit reduzieren. Bei entsprechendem Risiko sollten alternative Präparate eingesetzt oder die Indikation zur Therapie generell überdacht werden.

Abstract

Numerous drugs besides chemotherapeutic agents and anti-infectives that are regularly used in clinical routine can exacerbate or cause polyneuropathy. Knowledge about which substances are associated with polyneuropathies and patients’ risk factors can likely reduce the incidence of drug-induced polyneuropathies. In case of increased risk, alternative substances should be chosen or the indication for therapy should be reevaluated.

Schlüsselwörter

Medikament - Polyneuropathie - Nebenwirkung - Wirkstoff - Substanzklasse

Key words

drug - polyneuropathy - side effect - active substance - substance class

• Literatur

• 1 Jain KK. Drug-induced neurological disorders. [4. Auflage]. Berlin: Springer; 2021
• 2 Block F, Prüter C. Medikamentös induzierte neurologische und psychiatrische Störungen. Heidelberg: Springer Medizin Verlag; 2006
• 3 Grantz M, Huan MC. Unusual peripheral neuropathies. Part I: extrinsic causes. Semin Neurol 2010; 30: 387-395
• 4 Jin PH, Shin SC. Neuropathy of connective tissue diseases and other systemic diseases. Semin Neurol 2019; 39: 651-668
• 5 Karam C, Dyck PJ. Toxic neuropathies. Semin Neurol 2015; 35: 448-457
• 6 Pratt RW, Weimer LH. Medication and toxin-induced peripheral neuropathy. Semin Neurol 2005; 25: 204-216
• 7 Manji H. Drug-induced neuropathies. Handb Clin Neurol 2013; 115: 729-742
• 8 Pestronk A. Pestronk A. Toxic neuropathies.
• 9 Li Y. Axonal sensorimotor polyneuropathies. Continuum (Minneap Minn) 2017; 23: 1378-1393
• 10 Jones MR, Urits I, Wolf J. et al. Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol 2020; 15: 38-48
• 11 Niimi N, Takaku S, Yako H. et al. Drug-induced demyelinating neuropathies. Adv Exp Med Biol 2019; 1190: 357-369
• 12 England JD, Asbury AK. Peripheral neuropathy. Lancet 2004; 363: 2151-2161
• 13 Toledano M. Toxin-induced neuropathies. Neurol Clin 2020; 38: 749-763
• 14 Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol 2005; 18: 574-580
• 15 Peltier AC, Russell JW. Advances in understanding drug-induced neuropathies. Drug Saf 2006; 29: 23-30
• 16 Weimer LH. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2003; 3: 86-92
• 17 Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2009; 9: 69-75
• 18 Grisold W, Carozzi VA. Toxicity in peripheral nerves: an overview. Toxics 2021; 9 PMID: 34564369; PMCID: PMC8472820
• 19 Manji H. Toxic neuropathy. Curr Opin Neurol 2011; 24: 484-490
• 20 Miller JW. Proton pump inhibitors, H2-receptor antagonists, metformin, and vitamin B-12 deficiency: clinical implications. Adv Nutr 2018; 9: 511s-518s
• 21 Stübgen JP. Drug-induced dysimmune demyelinating neuropathies. J Neurol Sci 2011; 307: 1-8
• 22 Diezi M, Buclin T, Kuntzer T. Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and management. Curr Opin Neurol 2013; 26: 481-488
• 23 Kushlaf HA. Emerging toxic neuropathies and myopathies. Psychiatr Clin North Am 2013; 36: 209-218
• 24 Little AA, Albers JW. Clinical description of toxic neuropathies. Handb Clin Neurol 2015; 131: 253-296
• 25 Valentine WM. Toxic peripheral neuropathies: agents and mechanisms. Toxicol Pathol 2020; 48: 152-173
• 26 Finsterer J, Löscher WN, Wanschitz J. et al. Orphan peripheral neuropathies. J Neuromuscul Dis 2021; 8: 1-23
• 27 Farhad K, Traub R, Ruzhansky KM. et al. Causes of neuropathy in patients referred as “idiopathic neuropathy”. Muscle Nerve 2016; 53: 856-861
• 28 Gorzel KM, Dafotakis M, Holtbernd F. Nicht zum Lachen: eine Begleiterscheinung der Corona-Pandemie. Klinische Neurophysiologie 2021; 52: 213-214